New PET scan tracer could reveal hidden cancer markers
NCT ID NCT06383598
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new radioactive tracer called [68Ga]Ga-THP-PDL1-3 for PET/CT scans in 50 adults with solid tumors. The goal is to see if it can safely and accurately show PD-L1 levels in tumors, which may help doctors personalize cancer treatment. Participants will receive both the new tracer and a standard FDG scan. The study focuses on safety, image quality, and radiation dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[68Ga]Ga-THP-PDL1-3 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could provide a non-invasive way to see PD-L1 levels in tumors, helping doctors choose the right treatments and monitor response without repeated biopsies.
What could go wrong
This is a very early, small pilot study (50 people) focused on safety and feasibility, not on treatment outcomes. The tracer may not reliably reflect PD-L1 changes, and results may not apply to all cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••